Common TitleHBV-10: Heplisav-B versus Engerix-B in Healthy Adults 18-55 Years of Age
Official Title A Phase III Safety and Efficacy Study to Compare Immune Responses Following Injection With Either Two Doses of HEPLISAV™ or Three Doses of Engerix-B®
Purpose / DescriptionNote: 11-17 year olds eligible but only 13 of the 2428 randomized were age 11-17 years (most had previously received HBV vaccine as child as part of universal HBV vaccine program).
Phase Phase III
ClinicalTrials.gov NCT00435812
Treatments
Heplisav-B
Heplisav-B
Tradename:Heplisav-BOther Names:Hepatitis B Vaccine (Recombinant) Adjuvanted, HepB-CpGClass:Vaccines (HBV)Funding
IndustryDynavax Technologies Corporation